For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Amylyx Pharmaceuticals Inc’s stock clocked out at $12.0, down -1.56% from its previous closing price of $12.19. In other words, the price has decreased by -$1.56 from its previous closing price. On the day, 1.37 million shares were traded. AMLX stock price reached its highest trading level at $12.43 during the session, while it also had its lowest trading level at $11.915.
Ratios:
To gain a deeper understanding of AMLX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.70 and its Current Ratio is at 13.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 23 ’25 when Firestone Karen bought 8,100 shares for $12.45 per share. The transaction valued at 100,845 led to the insider holds 63,100 shares of the business.
Bedrosian Camille L sold 6,580 shares of AMLX for $94,418 on Dec 01 ’25. The Chief Medical Officer now owns 175,756 shares after completing the transaction at $14.35 per share. On Dec 01 ’25, another insider, Bedrosian Camille L, who serves as the Officer of the company, bought 6,580 shares for $14.35 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1317834752 and an Enterprise Value of 979779840. Its current Enterprise Value per Revenue stands at -1473.353 whereas that against EBITDA is -5.077.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.33, which has changed by 2.1176472 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $16.96, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is -10.97%, while the 200-Day Moving Average is calculated to be 33.18%.
Shares Statistics:
It appears that AMLX traded 1.60M shares on average per day over the past three months and 1827630 shares per day over the past ten days. A total of 109.77M shares are outstanding, with a floating share count of 91.68M. Insiders hold about 16.52% of the company’s shares, while institutions hold 94.74% stake in the company. Shares short for AMLX as of 1765756800 were 12068995 with a Short Ratio of 7.53, compared to 1763078400 on 11911669. Therefore, it implies a Short% of Shares Outstanding of 12068995 and a Short% of Float of 11.89.
Earnings Estimates
Amylyx Pharmaceuticals Inc (AMLX) is currently under the scrutiny of 9.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.15 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.22 and -$1.79 for the fiscal current year, implying an average EPS of -$1.53. EPS for the following year is -$1.25, with 8.0 analysts recommending between -$0.8 and -$1.64.
